Hostname: page-component-cd9895bd7-gbm5v Total loading time: 0 Render date: 2024-12-28T03:58:42.892Z Has data issue: false hasContentIssue false
  • English
  • Français

Acute myocarditis following COVID-19 mRNA vaccination: a paediatric case

Part of: Echocardiography

Published online by Cambridge University Press:  02 February 2022

Dilek Giray Open the ORCID record for Dilek Giray [Opens in a new window]  and
Serdar Epçaçan Open the ORCID record for Serdar Epçaçan [Opens in a new window]
Dilek Giray*
Affiliation:
Department of Pediatric Cardiology, Van Training and Research Hospital, Van, Turkey
Serdar Epçaçan
Affiliation:
Department of Pediatric Cardiology, Van Training and Research Hospital, Van, Turkey
*
Author for correspondence: D. Giray, Department of Pediatric Cardiology, Van Training and Research Hospital, TR- 65300, Van, Turkey. Tel: +90 535 647 8996; Fax: +90 432 2121954. E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Myocarditis is an inflammation of the heart muscle. In this case, a previously healthy, 17-year-old adolescent with myocarditis after BNT162b2 mRNA vaccination was reported. He was admitted to the hospital with severe chest pain, changes in electrocardiography, and elevation in serum troponin level after fourth day of receiving first dose of vaccine. There was no coronary arterial disease in coronary angiogram. A diagnosis of vaccine-induced myocarditis was made, and supportive treatment was initiated.

Keywords

COVID-19COVID-19 vaccinesmyocarditispericarditis
Type
Brief Report
Information
Cardiology in the Young , Volume 32 , Issue 7 , July 2022 , pp. 1178 - 1180
Check for updates
Copyright
© The Author(s), 2022. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

WHO coronavirus (COVID-19) dashboard. Retrieved December 5, 2021, from https://CoVID19.who.int Google Scholar
Garcia, JF, Ortega, PP, Fernandes, JAB, et al. Acute myocarditis after administration of the BNT162b2 vaccine against COVID-19. Rev Esp Cardiol 2021; 74: 812–814. DOI 10.1016/j.recesp.2021.03.009.10.1016/j.recesp.2021.03.009CrossRefGoogle Scholar
Mouch, SA, Roguin, A, Hellou, E, et al. Myocarditis following COVID-19 mRNA vaccination. Vaccine 2021; 39: 3790–3793. DOI 10.1016/j.vaccine.2021.05.087.10.1016/j.vaccine.2021.05.087CrossRefGoogle ScholarPubMed
Halsell, JS, Riddle, JR, Atwood, JE, et al. Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel. JAMA 2003; 289: 3283–3289. DOI 10.1001/jama.289.24.3283.CrossRefGoogle ScholarPubMed
Su, JR, McNeil, MM, Welsh, KJ, et al. Myopericarditis after vaccination, vaccine adverse event reporting system (VAERS), 1990-2018. Vaccine 2021; 39: 839–845. DOI 10.1016/j.vaccine.2020.12.046.10.1016/j.vaccine.2020.12.046CrossRefGoogle ScholarPubMed
Mei, R, Raschi, E, Forcesi, E, et al. Myocarditis and pericarditis after immunization: gaining insights through the vaccine adverse event reporting system. Int J Cardiol 2018; 273: 183–186. DOI 10.1016/j.ijcard.2018.09.054.10.1016/j.ijcard.2018.09.054CrossRefGoogle ScholarPubMed
Li, J, Hui, A, Zhang, X, et al. Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study. Nat Med 2021; 27: 1062–1070. DOI 10.1038/s41591-021-01330-9.10.1038/s41591-021-01330-9CrossRefGoogle ScholarPubMed
Inciardi, RM, Lupi, L, Zaccone, G, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020; 5: 819–824.10.1001/jamacardio.2020.1096CrossRefGoogle Scholar
Pfizer-BioNTech. Full emergency use autho- rization (EUA) prescribing information. Retrieved from http://labeling.pfizer.com/ShowLabeling.aspx?id=14471&format=pdf&#page=13 Google Scholar